Indian Pediatr. 2025 Feb 15;62(2):148-150. doi: 10.1007/s13312-025-3381-7.
ABSTRACT
The management of high-risk neuroblastoma has dismal outcomes in low-and-middle-income countries (LMICs). There is limited data on post transplant outcomes of high-risk neuroblastoma from LMICs. We report the outcomes of twelve patients with high-risk neuroblastoma who underwent autologous stem cell transplanatation (ASCT) at a single tertiary care center in Northen India. At a median follow-up of 25.5 months, the event-free survival was 63.6%. Relapse occurred in four patients (33.3%), who subsequently died. All patients had febrile neutropenia; there was no ASCT-related mortality. Multidisciplinary therapy even with omission of dinutuximab in our cohort had acceptable outcomes.
PMID:39912276 | DOI:10.1007/s13312-025-3381-7
